Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: Role of nitric oxide

Tamás Csont, Anikó Görbe, Erika Bereczki, Andrea Szunyog, Eda Aypar, Melinda E. Tóth, Zoltán V. Varga, Csaba Csonka, Ferenc Fülöp, Miklós Sántha, Péter Ferdinandy

Research output: Contribution to journalArticle

27 Citations (Scopus)


Biglycan, a proteoglycan component of extracellular matrix, has been suspected to contribute to the development of atherosclerosis, but overexpression of biglycan in transgenic mice has been shown to induce cardioprotective genes including nitric oxide (NO) synthases in the heart. Therefore, here we hypothesized if exogenous administration of biglycan exerts cytoprotection. Primary cardiomyocytes from neonatal rats were subjected to 150 min hypoxia and 2 h reoxygenation. Mortality of cardiomyocytes was dose-dependently attenuated by pretreatment with 1-100 nM biglycan. Biglycan enhanced eNOS mRNA and protein, and significantly increased NO content of cardiomyocytes. The NO synthase inhibitor l-nitro-arginine-methyl-ester significantly attenuated the cytoprotective effect of biglycan. This is the first demonstration that biglycan leads to cytoprotection against hypoxia/reoxygenation injury, and that this phenomenon is partially mediated by an NO-dependent mechanism.

Original languageEnglish
Pages (from-to)649-652
Number of pages4
JournalJournal of Molecular and Cellular Cardiology
Issue number4
Publication statusPublished - Apr 1 2010



  • Biglycan
  • Cytoprotection
  • Hypoxia/reoxygenation
  • Myocytes
  • Nitric oxide
  • Proteoglycans

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this